^
    Back
    Association details:
    Biomarker:HER-2 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The NCCN NSCLC Panel recommends ado-trastuzumab emtansine (category 2A) for patients with ERBB2 (also known as HER2) mutations...
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Eur Respir J
    Title:

    The efficacy of Ado-trastuzumab emtansine in HER-2 aberrant non-small cell lung cancer

    Excerpt:
    Subgroup analyses showed an ORR of 35.00% for HER-2 mutation, 42.86% for HER-2 gene amplification, and 2.78% for HER-2 protein overexpression...T-DM1 is a promising agent targeting HER-2 mutations or amplification in lung cancers, and the therapeutic efficacy may be better for cancers with HER-2 mutation plus amplification.